Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Diagnoplex SA and Unilabs Sign a Collaboration Agreement to Market the Colox® Non-Invasive Colon Cancer Screening Test

September 18, 2013

LAUSANNE, Switzerland, September 18, 2013 /PRNewswire/ –

Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs,
a leading supplier of clinical laboratory and medical diagnostic imaging services in
Europe, signed a collaboration agreement to commercialize Colox(R), a minimally invasive
colorectal cancer assay within the Unilabs network. The test will be available initially
in the Swiss and Swedish markets.

The agreement combines Diagnoplex’s capacity to develop “high-return” molecular assays
with Unilabs’ leading position in the European diagnostics market. The agreement builds on
a solid collaborative effort between the two companies and enables Unilabs to further
differentiate itself through innovative molecular testing.

“This agreement opens a new and exciting chapter for Diagnoplex,” said Stavros
Therianos, founder and CEO of Diagnoplex SA. “We are able to enter into a strong
collaboration with a European market leader such as Unilabs thanks to a patient-focused
strategy for clinical product development. This collaboration demonstrates that a
step-by-step approach, for the development of molecular screening tests, can effectively
lead to the commercial availability of medically relevant diagnostics.”

Fernando de Gorgolas, Unilabs Group Marketing & Business Development Director, said,
“This collaboration with Diagnoplex is consistent with our strategy of launching
innovative tests that can bring a real benefit to patients and the healthcare community.
Colox will strengthen the role of our molecular genetics laboratories in the diagnosis and
monitoring of colorectal cancer.”

Thierry Mauvernay, Delegate of the Board of Debiopharm Group – a lead investor in
Diagnoplex – agreed, adding, “We are delighted that Diagnoplex has been able to establish
this collaboration with an important actor in diagnostic market. We believe the Colox
blood test has the potential to greatly increase the percentage of people that will be
correctly screened for colorectal cancer.”

Other investors of Diagnoplex SA include NeoMed, Novartis Bioventures and Initiative
Capital Romandie. Bourgeois Avocats in Lausanne, Switzerland, were involved with legal
aspects of the collaboration agreement.

About Diagnoplex

Diagnoplex’s lead product, Colox(R), is a convenient and minimally invasive blood test
developed for the systematic screening of colorectal cancer. The gene signature underlying
Colox(R) has been designed to detect early and advanced disease stages with outstanding
results and reliability.

Colox(R) leverages the information from nucleic acids carried by peripheral blood
mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the
so-called “host response”, and are involved at the earliest stages of tumor formation. Our
ability to screen for the host response enables us to detect colorectal cancer risk at the
earliest and even pre-cancerous stages.

For more information about Diagnoplex, please visit: http://www.diagnoplex.com

About Unilabs

Unilabs is a leading diagnostic services company. We operate more than 120
laboratories and 44 radiology units in Denmark, Finland, France, Italy, Norway, Portugal,
Russia, Spain, Sweden, Switzerland, and the United Kingdom. Our customers are public and
private healthcare providers, county councils, the general public, insurance companies,
the pharmaceutical industry and CROs. We supply medical laboratory services within:
laboratory medicine, genetic testing, medical imaging, cellular pathology, reproductive
medicine, drug development services and clinical trials. For more information please visit

http://www.unilabs.com.

        Diagnoplex S.A. Contact
        Stavros Therianos, Ph.D.

        Chief Executive Officer

        Tel. +41-21-989-20-00
        stherianos@diagnoplex.com

        Unilabs Contact
        Fernando de Gorgolas
        Group Marketing & Business Development Director
        Tel. +41-22-909-77-77
        Fernando.DeGorgolas@unilabs.com

        Additional media contacts :
        London
        Maitland
        Brian Hudspith
        Tel.: +44(0)20-7379-5151
        bhudspith@maitland.co.uk

        New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        Tel.: +1-212-845-4292
        Fax: +1-212-845-4260
        martina.schwarzkopf@russopartnersllc.com

SOURCE Diagnoplex SA and Unilabs


Source: PR Newswire